FDA Inspection 1065832 — APHROZONE USA, INC.

APHROZONE USA, INC. — FEI 3012056155

The FDA completed an inspection of APHROZONE USA, INC. on September 17, 2018 in Los Angeles, CA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 1 citation was issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
September 17, 2018
Fiscal Year
2018
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Los Angeles, CA (United States)

Citations

IDCFRDescription
433621 CFR 211.150Written distribution procedure